Abstract #FRI-234: Efficacy and safety of Epclusa (sofosbuvir plus velpatasvir) in people with chronic hepatitis C virus infection and recent injecting drug use: The SIMPLIFY study—J. Grebely et. al.
Study Aims and Results: The study was an international study to evaluate the safety and effectiveness of sofosbuvir and velpatasvir in people infected with hepatitis C.
The people in the study included HCV Genotypes 1 (35%); 2 (5%); 3 (58%); 4 (2%), age <40yo 24%, female sex 28%, no opioid substitution therapy, but were injecting drugs 32%; opioid substitution and injecting drugs 42%, minimal/early fibrosis (F0-F1) 62% or early/severe fibrosis (F2-F3) 26%, cirrhosis (F-4) 9%.
The study recruited patients from 19 international sites. There were 114 people recruited for the study; 103 who started treatment. Three patients discontinued treatment who were lost to follow-up and there was one death. There was one case of relapse due to reinfection of hepatitis C. The cure rate was 94% (96 of 102 people).
There were very high cure rates and only one reinfection. The people in this trial will be followed for a period of three years.
The clinical trial validates that people who inject drugs who are on or off opioid substitution therapy can be successfully treated with direct-acting antiviral therapy. We need to treat people everyone with hepatitis C including injection drug users.Share This Page